These differences in MUC1 expression and glycosylation occur in over 75% of carcinomas, including breast, lung, pancreatic, epithelial ovarian, and prostate cancers, potentially making this protein immunogenic and a promising target for cancer immunotherapy [12]. Here, MUC1 is linked to carcinoma.